Watch Demo

Embolotherapy Global Market - Forecast to 2029

Embolotherapy Global Market - Forecast to 2029

  • Publish Date:January 2023

  • Number of Pages:449

  • Report ID:6377911

  • Format:PDF

  • Publisher:IQ4I Research & Consultancy Pvt. Ltd

$ 4950

Summary

Embolotherapy involves the percutaneous endovascular use of one or more of a variety of agents and has evolved as a minimally invasive procedure for controlling blood loss during complicated surgical procedures involving laparoscopic, neurovascular, uterine fibroids, arteriovenous malformations, hepatocellular carcinomas, benign prostate hyperplasia (BPH), neurovascular, intracranial and peripheral vasculatures related surgeries.

According to IQ4I analysis, the Embolotherapy global market is expected to grow at mid single digit CAGR from 2022 to 2029 to reach $6,115.9 million by 2029. The Embolotherapy market is segmented based on products, applications, procedures, end-users and geography. The Embolotherapy products market is segmented into temporary agents, permanent agents, Radioembolization, and supporting devices, among them, permanent agents held the largest share of the market in 2022 and are expected to grow at high single digit CAGR from 2022 to 2029. The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029. Temporary agents are further sub-segmented into autologous agents and Resorbable gelatin sponges, of this, the Resorbable gelatin sponge accounted for the largest share in 2022 and are expected to grow at mid single digit CAGR from 2022 to 2029. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolization agents, flow diverters and others, among which the coils segment commanded the largest share in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029. The particle agents are further segmented into poly vinyl alcohol (PVA) and microspheres, among which the microspheres segment commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The coils are further segmented into pushable and detachable coils among which the detachable coils commanded the largest share in 2022, the segment is expected to grow at low single digit CAGR from 2022 to 2029.

The applications market is segmented into neurology, oncology, peripheral vascular diseases, urology and others, among them, the neurology segment held the largest share of 44.5% in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The urology segment is expected to grow at high single digit CAGR from 2022 to 2029. The neurology application market is sub-segmented into the intracranial aneurysm and arteriovenous malformation (AVM), of this, the intracranial aneurysm segment command the largest revenue in 2022, the AVM segment is expected to grow at high single digit CAGR from 2022 to 2029. The oncology market is further sub-segmented into liver cancer, lung cancer, and others, of this, the lung cancer segment commanded the largest revenue in 2022 and the market is expected to grow at high single digit CAGR from 2022 to 2029.

Based on Procedures the embolotherapy global market is segmented into Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Chemoembolization (TACE), and Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), among them, TAE commanded the largest share in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029, the TARE/SIRT segmented is expected to grow at high single digit CAGR from 2022 to 2029. The Transcatheter Arterial Chemoembolization (TACE) market is segmented into drug-eluting beads-TACE and conventional TACE, among which the cTACE commanded the largest revenue in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029.

The end-users market is classified into hospitals, ambulatory surgical centers and others. Among them, the hospital commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is expected to grow at high single digit CAGR from 2022 to 2029.

Geographically, North America is the largest market, followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at high single digit CAGR from 2022 to 2029 presenting an array of growth opportunities and is likely to get the attention of new investors in the Embolotherapy market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.

On the other hand, side effects, complications, and risks associated with embolization and lack of skilled and trained professionals are restraining the market growth, while increasing product recalls, competition from alternative therapies and stringent regulatory requirements for product development and approvals are threatening the market growth.

The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the embolotherapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (U.S.), Stryker (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Sirtex (CDH) (China), Johnson & Johnson (U.S.), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (U.S.), Cook Medical (U.S.), Siemens Healthineers (Varian) (Germany), and Guerbet (France).

Table of contents

1 EXECUTIVE SUMMARY 26

2 INTRODUCTION 33
2.1 KEY TAKEAWAYS 33
2.2 SCOPE OF THE REPORT 34
2.3 REPORT DESCRIPTION 34
2.4 MARKETS COVERED 37
2.5 STAKEHOLDERS 38
2.6 RESEARCH METHODOLOGY 39
2.6.1 MARKET SIZE ESTIMATION 41
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 43
2.6.3 SECONDARY SOURCES 44
2.6.4 PRIMARY SOURCES 44
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 45
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 45
2.6.7 ASSUMPTIONS 46

3 MARKET ANALYSIS 48
3.1 INTRODUCTION 48
3.2 MARKET SEGMENTATION 49
3.3 FACTORS INFLUENCING MARKET 54
3.3.1 DRIVERS AND OPPORTUNITIES 55
3.3.1.1 Growing patient population with chronic conditions increasing the
demand for embolization procedures 55
3.3.1.2 Technological advancements 56
3.3.1.3 Acquisitions and collaborations as a growth strategy 58
3.3.1.4 Increase in product approvals 58
3.3.1.5 Growth opportunities in emerging markets 59
3.3.2 RESTRAINTS AND THREATS 60
3.3.2.1 Side effects, complications, and risks associated with embolization 60
3.3.2.2 Lack of skilled and trained professionals 61
3.3.2.3 Increasing product recalls 62
3.3.2.4 Competition from alternative therapies 62
3.3.2.5 Stringent regulatory requirements for product development
and approvals 63
3.4 REGULATORY AFFAIRS 65
3.4.1 THE U.S. 65
3.4.2 CHINA 66
3.4.3 EUROPE 68
3.4.4 JAPAN 69
3.4.5 INDIA 72
3.5 FUNDING 73
3.6 DEALS 77
3.7 PRODUCT APPROVALS AND LAUNCHES 79
3.8 TECHNOLOGY ADVANCEMENTS 86
3.8.1 GPX EMBOLIC DEVICE 86
3.8.2 HYDRAULICALLY ACTUATED SOFT ROBOTIC STEERABLE
MICRO-CATHETER 86
3.8.3 SHAPE MEMORY POLYMER (SMP) TECHNOLOGY 87
3.8.4 BIODEGRADABLE EMBOLIZATION AGENTS 87
3.8.5 EMBOLIZATION IN PAIN MANAGEMENT OF OSTEOARTHRITIS 88
3.8.6 INSTYLLA-HYDROGEL EMBOLIC SYSTEM (HES) 89
3.8.7 MICROFLUIDICS IN MANUFACTURING OF MICROSPHERES 89
3.8.8 MICROBOTS IN SWARMS FOR EMBOLIZATION 90
3.8.9 BISMUTH (BI)-BASED LIQUID EMBOLIC AGENT 91
3.8.10 FAIR-EMBO PROJECT 91
3.8.11 BIOCURE-LIQIGEL AGENT 92
3.8.12 WATER SOLUBLE POLYMERS AS EMBOLIC AGENT 93
3.8.13 NANOPARTICLES IN TUMOR EMBOLIZATION THERAPY 93
3.8.14 GAS EMBOLIZATION (GE) USING ACOUSTIC DROPLET VAPORIZATION(ADV) TECHNOLOGY 95
3.9 PORTER'S FIVE FORCE ANALYSIS 96
3.9.1 THREAT OF NEW ENTRANTS 97
3.9.2 THREAT OF SUBSTITUTES 98
3.9.3 COMPETITIVE RIVALRY 98
3.9.4 BARGAINING POWER OF SUPPLIERS 99
3.9.5 BARGAINING POWER OF BUYERS 99
3.10 CLINICAL TRIALS 99
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 102
3.11.1 EMBOLOTHERAPY MARKET SHARE ANALYSIS 102
3.11.2 COILS MARKET SHARE ANALYSIS 106
3.11.3 FLOW DIVERTERS & DISRUPTORS MARKET SHARE ANALYSIS 109
3.11.4 RADIOEMBOLIZATION MARKET SHARE ANALYSIS 111
3.12 VOLUME OF NEUROVASCULAR COIL-ASSISTED PROCEDURES 113
3.12.1 NEUROVASCULAR COILS GLOBAL MARKET 113
3.13 PRODUCT MATRIX OF SELECTED COMPANIES 119

4 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PRODUCTS 129
4.1 INTRODUCTION 129
4.2 TEMPORARY AGENTS 131
4.2.1 AUTOLOGOUS AGENTS 135
4.2.2 RESORBABLE GELATIN SPONGE 136
4.3 PERMANENT AGENTS 139
4.3.1 PARTICLE AGENTS 143
4.3.1.1 Poly vinyl alcohol (PVA) 147
4.3.1.2 Microspheres 149
4.3.2 COILS 151
4.3.2.1 Pushable Coils 156
4.3.2.2 Detachable Coils 159
4.3.3 LIQUID EMBOLIZATION AGENTS (LEAS) 162
4.3.4 FLOW DIVERTERS & FLOW DISRUPTORS 165
4.3.5 OTHERS 169
4.4 RADIOEMBOLIZATION 172
4.5 SUPPORTING DEVICES 174

5 EMBOLOTHERAPY GLOBAL MARKET, BASED ON THE APPLICATION 177
5.1 INTRODUCTION 177
5.2 NEUROLOGY 180
5.2.1 INTRACRANIAL ANEURYSM 184
5.2.2 ARTERIOVENOUS MALFORMATIONS (AVM) 187
5.3 ONCOLOGY 191
5.3.1 LIVER CANCER 194
5.3.2 LUNG CANCER 196
5.3.3 OTHER CANCER 198
5.4 PERIPHERAL VASCULAR DISEASES (PVD) 201
5.5 UROLOGY 206
5.6 OTHER APPLICATIONS 210

6 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PROCEDURE 214
6.1 INTRODUCTION 214
6.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) 217
6.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) 219
6.3.1 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE) 223
6.3.2 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION
(cTACE) 224
6.4 TRANS-ARTERIAL EMBOLIZATION(TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 226

7 EMBOLOTHERAPY GLOBAL MARKET, BASED ON END-USER 230
7.1 INTRODUCTION 230
7.2 HOSPITALS 233
7.3 AMBULATORY SURGICAL CENTERS 235
7.4 OTHER END-USERS 236

8 EMBOLOTHERAPY GLOBAL MARKET, BASED ON REGION 238
8.1 INTRODUCTION 238
8.2 NORTH AMERICA 242
8.2.1 U.S. 264
8.2.2 REST OF NORTH AMERICA 268
8.3 EUROPE 272
8.3.1 GERMANY 294
8.3.2 FRANCE 298
8.3.3 ITALY 301
8.3.4 REST OF EUROPE 305
8.4 APAC 309
8.4.1 JAPAN 332
8.4.2 CHINA 335
8.4.3 INDIA 338
8.4.4 REST OF APAC 342
8.5 REST OF THE WORLD 346
8.5.1 BRAZIL 368
8.5.2 REST OF SOUTH AMERICA 372
8.5.3 MIDDLE EAST AND AFRICA 376

9 COMPETITIVE LANDSCAPE 380
9.1 INTRODUCTION 380
9.2 APPROVAL 381
9.3 ACQUISITION 385
9.4 AGREEMENTS 385
9.5 NEW PRODUCT LAUNCH 386
9.6 OTHERS 387

10 MAJOR COMPANIES 389
10.1 BALT GROUP 389
10.1.1 OVERVIEW 389
10.1.2 FINANCIALS 389
10.1.3 PRODUCT PORTFOLIO 390
10.1.4 KEY DEVELOPMENTS 390
10.1.5 BUSINESS STRATEGY 391
10.1.6 SWOT ANALYSIS 392
10.2 BOSTON SCIENTIFIC CORPORATION 393
10.2.1 OVERVIEW 393
10.2.2 FINANCIALS 394
10.2.3 PRODUCT PORTFOLIO 397
10.2.4 KEY DEVELOPMENTS 398
10.2.5 BUSINESS STRATEGY 399
10.2.6 SWOT ANALYSIS 400
10.3 JOHNSON & JOHNSON 401
10.3.1 OVERVIEW 401
10.3.2 FINANCIALS 402
10.3.3 PRODUCT PORTFOLIO 403
10.3.4 KEY DEVELOPMENTS 404
10.3.5 BUSINESS STRATEGY 404
10.3.6 SWOT ANALYSIS 405
10.4 KANEKA CORPORATION 406
10.4.1 OVERVIEW 406
10.4.2 FINANCIALS 407
10.4.3 PRODUCT PORTFOLIO 409
10.4.4 KEY DEVELOPMENTS 410
10.4.5 BUSINESS STRATEGY 410
10.4.6 SWOT ANALYSIS 411
10.5 MEDTRONIC, PLC 412
10.5.1 OVERVIEW 412
10.5.2 FINANCIALS 413
10.5.3 PRODUCT PORTFOLIO 417
10.5.4 KEY DEVELOPMENTS 418
10.5.5 BUSINESS STRATEGY 418
10.5.6 SWOT ANALYSIS 419
10.6 MERIT MEDICAL SYSTEMS, INC 420
10.6.1 OVERVIEW 420
10.6.2 FINANCIALS 421
10.6.3 PRODUCT PORTFOLIO 424
10.6.4 KEY DEVELOPMENTS 425
10.6.5 BUSINESS STRATEGY 426
10.6.6 SWOT ANALYSIS 427
10.7 PENUMBRA, INC 428
10.7.1 OVERVIEW 428
10.7.2 FINANCIALS 429
10.7.3 PRODUCT PORTFOLIO 430
10.7.4 KEY DEVELOPMENTS 431
10.7.5 BUSINESS STRATEGY 431
10.7.6 SWOT ANALYSIS 432
10.8 SIRTEX MEDICAL INC. 433
10.8.1 OVERVIEW 433
10.8.2 FINANCIALS 433
10.8.3 PRODUCT PORTFOLIO 433
10.8.4 KEY DEVELOPMENTS 434
10.8.5 BUSINESS STRATEGY 435
10.8.6 SWOT ANALYSIS 436
10.9 STRYKER CORPORATION 437
10.9.1 OVERVIEW 437
10.9.2 FINANCIALS 438
10.9.3 PRODUCT PORTFOLIO 440
10.9.4 KEY DEVELOPMENTS 441
10.9.5 BUSINESS STRATEGY 441
10.9.6 SWOT ANALYSIS 441
10.10 TERUMO CORPORATION 442
10.10.1 OVERVIEW 442
10.10.2 FINANCIALS 443
10.10.3 PRODUCT PORTFOLIO 444
10.10.4 KEY DEVELOPMENTS 445
10.10.5 BUSINESS STRATEGY 447
10.10.6 SWOT ANALYSIS 448

LIST OF TABLES
TABLE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 31
TABLE 2 NEUROVASCULAR COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 113
TABLE 3 NUMBER OF NEUROVASCULAR COILS UNITS SOLD GLOBALLY,
BASED ON REGION (2021-2029) (NOS) 114
TABLE 4 INTRACRANIAL ANEURYSM GLOBAL PROCEDURAL VOLUME,
BASED ON REGION, (2021-2029) ($MN) 115
TABLE 5 NEUROVASCULAR COIL UNITS SOLD AND INTRACRANIAL ANEURYSM PROCEDURES, BASED ON COUNTRIES (2022) (NOS) 116
TABLE 6 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 130
TABLE 7 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 132
TABLE 8 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN) 133
TABLE 9 AUTOLOGOUS AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 135
TABLE 10 RESORBABLE GELATIN SPONGE GLOBAL MARKET REVENUE,
BASED ON REGION (2021-2029) ($MN) 137
TABLE 11 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN) 140
TABLE 12 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 142
TABLE 13 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 144
TABLE 14 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 145
TABLE 15 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 148
TABLE 16 MICROSPHERES GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 150
TABLE 17 COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 153
TABLE 18 COILS GLOBAL MARKET REVENUE, BASED ON DEPLOYMENT
(2021-2029) ($MN) 155
TABLE 19 PUSHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 158
TABLE 20 DETACHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 161
TABLE 21 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN) 164
TABLE 22 FLOW DIVERTERS & FLOW DISRUPTORS GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN) 169
TABLE 23 OTHER GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 171
TABLE 24 RADIOEMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 174
TABLE 25 SUPPORTING DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 176
TABLE 26 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN) 178
TABLE 27 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 181
TABLE 28 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION
(2021-2029) ($MN) 182
TABLE 29 INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN) 186
TABLE 30 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 189
TABLE 31 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 192
TABLE 32 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION
(2021-2029) ($MN) 193
TABLE 33 LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 196
TABLE 34 LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 197
TABLE 35 OTHER CANCER GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 200
TABLE 36 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 205
TABLE 37 UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 210
TABLE 38 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 213
TABLE 39 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PROCEDURE (2021-2029) ($MN) 215
TABLE 40 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 218
TABLE 41 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 221
TABLE 42 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN) 222
TABLE 43 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 224
TABLE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 225
TABLE 45 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN) 227
TABLE 46 TAE AND DEB-TACE PRODUCTS MATRIX 228
TABLE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON END-USER
(2021-2029) ($MN) 231
TABLE 48 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) 234
TABLE 49 AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE,
BASED ON REGION (2021-2029) ($MN) 236
TABLE 50 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 237
TABLE 51 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION,
(2021-2029) ($MN) 239
TABLE 52 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN) 245
TABLE 53 NORTH AMERICAN TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN) 246
TABLE 54 NORTH AMERICAN PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN) 248
TABLE 55 NORTH AMERICAN PARTICLE AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN) 249
TABLE 56 NORTH AMERICAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN) 251
TABLE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON APPLICATION, (2021-2029) ($MN) 252
TABLE 58 NORTH AMERICAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN) 254
TABLE 59 NORTH AMERICAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN) 256
TABLE 60 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON PROCEDURE, (2021-2029) ($MN) 258
TABLE 61 NORTH AMERICAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN) 259
TABLE 62 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON END-USER (2021-2029) ($MN) 261
TABLE 63 NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON COUNTRY (2021-2029) ($MN) 263
TABLE 64 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 275
TABLE 65 EUROPEAN TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 276
TABLE 66 EUROPEAN PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 278
TABLE 67 EUROPEAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 279
TABLE 68 EUROPEAN COILS MARKET REVENUE, BASED ON DEPLOYMENT
(2021-2029) ($MN) 281
TABLE 69 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN) 282
TABLE 70 EUROPEAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION
(2021-2029) ($MN) 284
TABLE 71 EUROPEAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION,
(2021-2029) ($MN) 286
TABLE 72 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN) 288
TABLE 73 EUROPEAN TACE MARKET REVENUE, BASED ON THERAPY AGENT
(2021-2029) ($MN) 290
TABLE 74 EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER
(2021-2029) ($MN) 291
TABLE 75 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN) 293
TABLE 76 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 312
TABLE 77 ASIA-PACIFIC TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCT (2021-2029) ($MN) 313
TABLE 78 ASIA-PACIFIC PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN) 315
TABLE 79 ASIA-PACIFIC PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN) 316
TABLE 80 ASIA-PACIFIC COILS MARKET REVENUE, BASED ON DEPLOYMENT
(2021-2029) ($MN) 318
TABLE 81 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE,
BASED ON APPLICATION, (2021-2029) ($MN) 319
TABLE 82 ASIA-PACIFIC NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN) 321
TABLE 83 ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN) 323
TABLE 84 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN) 325
TABLE 85 ASIA-PACIFIC TACE MARKET REVENUE, BASED ON THERAPY AGENT
(2021-2029) ($MN) 327
TABLE 86 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN) 329
TABLE 87 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN) 331
TABLE 88 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS
(2021-2029) ($MN) 349
TABLE 89 ROW TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCT
(2021-2029) ($MN) 350
TABLE 90 ROW PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS
(2021-2029) ($MN) 352
TABLE 91 ROW PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS
(2021-2029) ($MN) 353
TABLE 92 ROW COILS MARKET REVENUE, BASED ON DEPLOYMENT
(2021-2029) ($MN) 355
TABLE 93 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION,
(2021-2029) ($MN) 356
TABLE 94 ROW NEUROLOGY MARKET REVENUE, BASED ON INDICATION
(2021-2029) ($MN) 358
TABLE 95 ROW ONCOLOGY MARKET REVENUE, BASED ON INDICATION,
(2021-2029) ($MN) 360
TABLE 96 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE,
(2021-2029) ($MN) 362
TABLE 97 ROW TACE MARKET REVENUE, BASED ON THERAPY AGENTS
(2021-2029) ($MN) 364
TABLE 98 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER
(2021-2029) ($MN) 365
TABLE 99 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY
(2021-2029) ($MN) 367
TABLE 100 APPROVALS (2020-2022) 381
TABLE 101 ACQUISITION (2020-2022) 385
TABLE 102 AGREEMENTS (2020-2022) 386
TABLE 103 NEW PRODUCT LAUNCH (2020-2022) 386
TABLE 104 OTHERS (2020-2022) 387
TABLE 105 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022)(Q3) ($MN) 394
TABLE 106 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN) 395
TABLE 107 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR SUB-SEGMENT TOTAL REVENUE, (2022)(Q3) ($MN) 396
TABLE 108 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN) 397
TABLE 109 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q2)($MN) 402
TABLE 110 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q2) ($MN) 402
TABLE 111 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q2) ($MN) 403
TABLE 112 KANEKA CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q2) ($MN) 407
TABLE 113 KANEKA CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q2) ($MN) 408
TABLE 114 KANEKA CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q2) ($MN) 409
TABLE 115 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q2) ($MN) 413
TABLE 116 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q2) ($MN) 414
TABLE 117 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE,
BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN) 415
TABLE 118 MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE,
BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN) 416
TABLE 119 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q2) ($MN) 417
TABLE 120 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN) 421
TABLE 121 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN) 422
TABLE 122 MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN) 423
TABLE 123 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN) 424
TABLE 124 PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q3) ($MN) 429
TABLE 125 PENUMBRA, INC: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q3) ($MN) 429
TABLE 126 PENUMBRA, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q3)($MN) 430
TABLE 127 STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q3) ($MN) 438
TABLE 128 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q3) ($MN) 438
TABLE 129 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN) 439
TABLE 130 STRYKER CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q3) ($MN) 440
TABLE 131 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2020-2022) (Q2) ($MN) 443
TABLE 132 TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS,
(2020-2022) (Q2) ($MN) 443
TABLE 133 TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY,
(2020-2022) (Q2) ($MN) 444

LIST OF FIGURES
FIGURE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) 32
FIGURE 2 RESEARCH METHODOLOGY: EMBOLOTHERAPY GLOBAL MARKET 40
FIGURE 3 EMBOLOTHERAPY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 41
FIGURE 4 EMBOLOTHERAPY GLOBAL MARKET: FORECASTING MODEL 42
FIGURE 5 EMBOLOTHERAPY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 6 EMBOLOTHERAPY GLOBAL MARKET SEGMENTATION 50
FIGURE 7 EMBOLOTHEAPY PRODUCTS GLOBAL MARKET SEGMENTATION 51
FIGURE 8 EMBOLOTHEAPY APPLICATION GLOBAL MARKET SEGMENTATION 52
FIGURE 9 EMBOLOTHEAPY PROCEDURES GLOBAL MARKET SEGMENTATION 53
FIGURE 10 MARKET DYNAMICS 54
FIGURE 11 EMBOLOTHERAPY GLOBAL MARKET: PORTER'S ANALYSIS 96
FIGURE 12 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON PHASES 100
FIGURE 13 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON CONDITION 101
FIGURE 14 EMBOLOTHERAPY GLOBAL MARKET SHARE ANALYSIS
BY MAJOR PLAYERS, 2022 (%) 102
FIGURE 15 COILS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%) 106
FIGURE 16 FLOW DIVERTERS & DISRUPTORS GLOBAL MARKET SHARE ANALYSIS
BY MAJOR PLAYERS, 2022 (%) 109
FIGURE 17 RADIOEMBOLIZATION GLOBAL MARKET SHARE ANALYSIS
BY MAJOR PLAYERS, 2022 (%) 111
FIGURE 18 NEUROVASCULAR COILS NO. OF UNITS SOLD, BASED ON REGION AND COUNTRIES, (2022) (NOS) 117
FIGURE 19 INTRACRANIAL ANEURYSM NO. OF PROCEDURES, BASED ON REGION AND COUNTRIES, (2022) (NOS) 118
FIGURE 20 EMBOLOTHEAPY GLOBAL MARKET SHARE, BASED ON PRODUCT,
(2022 V/S 2029) (%) 131
FIGURE 21 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 133
FIGURE 22 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%) 134
FIGURE 23 RESORBABLE GELATIN SPONGE GLOBAL MARKET SHARE,
BASED ON REGION, (2022 V/S 2029) (%) 138
FIGURE 24 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCT,
(2022 V/S 2029) (%) 141
FIGURE 25 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 143
FIGURE 26 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 145
FIGURE 27 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS
(2022 V/S 2029) (%) 146
FIGURE 28 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 149
FIGURE 29 COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%) 154
FIGURE 30 COILS GLOBAL MARKET SHARE, BASED ON DEPLOYMENT
(2022 V/S 2029) (%) 156
FIGURE 31 PUSHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 159
FIGURE 32 DETACHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 162
FIGURE 33 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET SHARE,
BASED ON REGION, (2022 V/S 2029) (%) 165
FIGURE 34 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022)(%) 179
FIGURE 35 NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 182
FIGURE 36 NEUROLOGY GLOBAL MARKET SHARE, BASED ON INDICATION
(2022 V/S 2029) (%) 183
FIGURE 37 INTRACRANIAL ANEURYSM GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 187
FIGURE 38 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET SHARE,
BASED ON REGION, (2022 V/S 2029) (%) 190
FIGURE 39 ONCOLOGY GLOBAL MARKET SHARE, BASED ON INDICATION
(2022 V/S 2029) (%) 194
FIGURE 40 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET SHARE,
BASED ON REGION, (2022 V/S 2029) (%) 206
FIGURE 41 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON PROCEDURE,
(2022 V/S 2029) (%) 216
FIGURE 42 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%) 219
FIGURE 43 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET SHARE, BASED ON THERAPY AGENT, (2022 V/S 2029) (%) 223
FIGURE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (cTACE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%) 226
FIGURE 45 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON END-USER
(2022 V/S 2029) (%) 232
FIGURE 46 HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION,
(2022 V/S 2029) (%) 235
FIGURE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION
(2021-2029) ($MN) CAGR (%) 240
FIGURE 48 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON REGIONAL MARKET REVENUE (2022) (%) ($MN) 241
FIGURE 49 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%) 246
FIGURE 50 NORTH AMERICAN TEMPORARY AGENTS MARKET SHARE,
BASED ON PRODUCT (2022 V/S 2029) (%) 247
FIGURE 51 NORTH AMERICAN PERMANENT AGENTS MARKET SHARE,
BASED ON PRODUCTS (2022 V/S 2029) (%) 249
FIGURE 52 NORTH AMERICAN PARTICLE AGENTS MARKET SHARE,
BASED ON PRODUCTS (2022 V/S 2029) (%) 250
FIGURE 53 NORTH AMERICA COILS MARKET SHARE, BASED ON DEPLOYMENT,
(2022 V/S 2029) (%) 251
FIGURE 54 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE,
BASED ON APPLICATION, (2022) (%) 253
FIGURE 55 NORTH AMERICAN NEUROLOGY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 255
FIGURE 56 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE,
BASED ON INDICATION, (2022 V/S 2029) (%) 257
FIGURE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE,
BASED ON PROCEDURE, (2022 V/S 2029) (%) 259
FIGURE 58 NORTH AMERICAN TACE MARKET SHARE, BASED ON THERAPY AGENTS,
(2022 V/S 2029) (%) 260
FIGURE 59 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%) 262
FIGURE 60 NORTH AMERICA EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY
(2022 V/S 2029) (%) 263
FIGURE 61 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN) 266
FIGURE 62 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN) 267
FIGURE 63 REST OF NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN) 270
FIGURE 64 REST NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN) 271
FIGURE 65 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT,
(2022 V/S 2029) (%) 276
FIGURE 66 EUROPEAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%) 277
FIGURE 67 EUROPEAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%) 279
FIGURE 68 EUROPEAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS
(2022 V/S 2029) (%) 280
FIGURE 69 EUROPEAN COILS MARKET SHARE, BASED ON DEPLOYMENT,
(2022 V/S 2029) (%) 281
FIGURE 70 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION,
(2022) (%) 283
FIGURE 71 EUROPEAN NEUROLOGY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 285
FIGURE 72 EUROPEAN ONCOLOGY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 287
FIGURE 73 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE,
(2022 V/S 2029) (%) 289
FIGURE 74 EUROPEAN TACE MARKET SHARE, BASED ON THERAPY AGENTS,
(2022 V/S 2029) (%) 290
FIGURE 75 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER
(2022 V/S 2029) (%) 292
FIGURE 76 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY
(2022 V/S 2029) (%) 293
FIGURE 77 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 296
FIGURE 78 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 297
FIGURE 79 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 300
FIGURE 80 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 301
FIGURE 81 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 303
FIGURE 82 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 304
FIGURE 83 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 307
FIGURE 84 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE,
BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 308
FIGURE 85 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT,
(2022 V/S 2029) (%) 313
FIGURE 86 ASIA-PACIFIC TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT
(2022 V/S 2029) (%) 314
FIGURE 87 ASIA-PACIFIC PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%) 316
FIGURE 88 ASIA-PACIFIC PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS
(2022 V/S 2029) (%) 317
FIGURE 89 ASIA-PACIFIC COILS MARKET SHARE, BASED ON DEPLOYMENT,
(2022 V/S 2029) (%) 318
FIGURE 90 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%) 320
FIGURE 91 ASIA-PACIFIC NEUROLOGY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 322
FIGURE 92 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 324
FIGURE 93 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE,
(2022 V/S 2029) (%) 326
FIGURE 94 ASIA-PACIFIC TACE MARKET SHARE, BASED ON THERAPY AGENTS,
(2022 V/S 2029) (%) 328
FIGURE 95 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER
(2022 V/S 2029) (%) 330
FIGURE 96 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY
(2022 V/S 2029) (%) 332
FIGURE 97 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 334
FIGURE 98 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND
END-USERS (2022 V/S 2029) ($MN) 335
FIGURE 99 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 337
FIGURE 100 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND
END-USERS (2022 V/S 2029) ($MN) 338
FIGURE 101 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN) 340
FIGURE 102 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND
END-USER (2022 V/S 2029) ($MN) 341
FIGURE 103 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 344
FIGURE 104 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 345
FIGURE 105 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCTS,
(2022 V/S 2029) (%) 350
FIGURE 106 ROW TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT
(2022 V/S 2029) (%) 351
FIGURE 107 ROW PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS
(2022 V/S 2029) (%) 353
FIGURE 108 ROW PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS
(2022 V/S 2029) (%) 354
FIGURE 109 ROW COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029)(%) 355
FIGURE 110 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022)(%) 357
FIGURE 111 ROW NEUROLOGY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 359
FIGURE 112 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION,
(2022 V/S 2029) (%) 361
FIGURE 113 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE,
(2022 V/S 2029) (%) 363
FIGURE 114 ROW TACE MARKET SHARE, BASED ON THERAPY AGENTS,
(2022 V/S 2029) (%) 365
FIGURE 115 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER
(2022 V/S 2029) (%) 366
FIGURE 116 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY
(2022 V/S 2029) (%) 367
FIGURE 117 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 370
FIGURE 118 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND
END-USERS (2022 V/S 2029) ($MN) 371
FIGURE 119 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 374
FIGURE 120 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN) 375
FIGURE 121 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN) 378
FIGURE 122 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN) 379
FIGURE 123 KEY GROWTH STRATEGIES (2020-2022) 380
FIGURE 124 SWOT: BALT GROUP 392
FIGURE 125 SWOT: BOSTON SCIENTIFIC CORPORATION 400
FIGURE 126 SWOT: SIRTEX MEDICAL INC. 436
FIGURE 127 SWOT: JOHNSON & JOHNSON 405
FIGURE 128 SWOT: KANEKA CORPORATION 411
FIGURE 129 SWOT: MEDTRONIC, PLC 419
FIGURE 130 SWOT: MERIT MEDICAL SYSTEMS, INC. 427
FIGURE 131 SWOT: PENUMBRA 432
FIGURE 132 SWOT: STRYKER 441
FIGURE 133 SWOT: TERUMO CORPORATION 448

Companies Mentioned
• BALT GROUP
• BOSTON SCIENTIFIC CORPORATION
• SIRTEX MEDICAL INC.
• JOHNSON & JOHNSON
• KANEKA CORPORATION
• MEDTRONIC, PLC
• MERIT MEDICAL SYSTEMS, INC.
• PENUMBRA
• STRYKER
• TERUMO CORPORATION
• LIST OF COMPANIES MENTIONED IN THE REPORT
• ACANDIS GMBH
• ANDRATEC GMBH
• ARTIO MEDICAL
• ARTVENTIVE MEDICAL GROUP, INC.
• ASAHI INTECC CO., LTD
• B.BRAUN MELSUNGEN
• BALT GROUP
• BECTON, DICKINSON AND COMPANY
• BOSTON SCIENTIFIC CORP.
• BRAILE BIOMEDICA INDUSTRIA
• CERUS ENDOVASCULAR
• COOK MEDICAL
• CRANNMED LIMITED
• EMBOLX, INC.
• GEM SRL
• GUERBET
• IMBIOTECHNOLOGIES, LTD.
• INVAMED
• JOHNSON & JOHNSON
• KANEKA CORP.
• LEPU MEDICAL
• LIFETECH SCIENTIFIC CORP.
• MEDTRONIC
• MERIL LIFE SCIENCES
• MERIT MEDICAL
• MICROPORT
• NEXT BIOMEDICAL CO., LTD
• OKAMI MEDICAL, INC
• PEIJIA MEDICAL
• PENUMBRA, INC.
• PFIZER
• PHARMACEPT GMBH
• PHENOX
• PIOLAX MEDICAL DEVICES, INC.
• PL MICROMED CO., LTD
• QMEDICS AG
• RAPID MEDICAL
• SCITECH MEDICAL
• SHAPE MEMORY MEDICAL
• SIEMENS HEALTHINEERS (VARIAN)
• SIRTEX
• SOLID MEDICAL SYSTEMS
• SPARTAN MICRO
• STRYKER
• SUZHOU HENGRUI CALLISYN BIOMEDICAL CO., LTD.
• SUZHOU HENGRUI DISHENG MEDICAL CO., LTD
• TELEFLEX
• TERUMO CORPORATION
• WALLABY MEDICAL
• WEGO HEALTHCARE (SHENZHEN) CO., LTD.
• ZYLOX-TONBRIDGE MEDICAL TECH.CO. LTD

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.